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Abstract 
Purpose: To analyze the potential of Allium sativum bulb extract in curing premature aging using 
reverse docking method. 
Methods: Ligand samples were retrieved from a PubChem database, allicin CID 65036, 
epigallocatechin gallate CID 65064, and pedunculagin CID 442688. To improve reliability, protein 
targets were predicted using three web services (PharmMapper, SuperPred and Swiss Target 
Prediction). Molecular docking was conducted to predict the interaction between Allium sativum 
bioactive as ligands and leukocyte elastase as protein target using PyRx 0.8 software. To be sure of the 
drug potential of the bioactive, DruLiTo software was used for the evaluation. Visualization and 
interaction analysis were performed by PyMol and Ligplus software.  
Results: The results showed that allicin has the highest potential as a candidate for premature-aging 
treatment, as evidenced by the highest binding affinity (-8.7 kcal/mol) to leukocyte elatase compared 
with epigallocatechin (-7.2 kcal/mol) and pedunculagin (-7.8 kcal/mol). Allicin acted as a leukocyte 
elatase inhibitor, with its binding stability facilitated by hydrogen bonding and hydrophobic interactions.  
Conclusion: Allicin has a potential as a leukocyte elastase inhibitor based on its binding affinity and 
intermolecular interactions. Thus, allicin is a potential anti-aging drug candidate based on Lipinski’s rule. 
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The presence of free radicals can cause various 
diseases including premature aging [1]. Skin 
aging is a complex evitable process for all living 
organisms [2,3]. There are several skincare 
cosmetics that can treat premature aging, but 
many of them can have adverse reactions 
including allergic contact dermatitis, irritant 
contact dermatitis, as well as phototoxic and 
photoallergic reactions [2,4]. To avoid some of 
these adverse effects, recently, anti-aging 
research has focused on scientific validation of 
natural products, often used throughout history 
for their medicinal properties [5]. Natural 
products like fruit, vegetables, spices provide 
antioxidant bioactive compounds and have been 
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widely used as a cosmetics historically and to the 
present day in some societies [6]  
 
Garlic (Allium sativum L.) is a well-known spices 
used in daily life especially for foodstuff and 
medicines in many cultures. Many people used 
garlic to prevent and treat several diseases [7,8]. 
Treatments using this herbal medicine need 
further verification to understand the mechanism 
of its activity. One useful bioinformatic-based 
method to reveal and understand the potential of 
A. sativum is the reverse docking method. This 
technique is popular for predicting the interaction 
between active compound and protein target. 
 
Most of the active compounds from A. sativum 
have phenolic groups. Allicin is the main 
bioactive component [11,12]. Allicin has a strong 
antioxidant activity as a protective compounds 
against free radical damage [13-15]. It has been 
observed experimentally that allicin can cure 
premature aging. [16,17]. This research aimed to 
analyze the potential of allicin  in A. sativum in 







The chemical 3D structure and SMILES of ligand 
(allicin CID 65036, epigallocatechin gallate CID 
65064, and pedunculagin CID 442688) were 
retrieved from the PubChem compound 
database (https://pubchem.ncbi.nlm.nih.gov/). 
 
Target selection and molecular docking 
analysis 
 
Ligands structure were analyzed using 
Pharmmapper (http://lilab.ecust.edu.cn) to 
identify target protein based on pharmacophore 
mapping approach [10] and ligands SMILES 
format were analysed using SuperPred 
(http://prediction.charite.de/) for identifying the 
target protein based on combination of 
physicochemical properties and similarity [18]. 
The specific protein target of A. sativum ligands 
was predicted using Swiss Target Prediction 
(http://swisstargetprediction.ch) [19]. Molecular 
docking of allicin, epigallocatechin and 
pedunculagin analysis was done using Pyrx 0.8. 
We used reference inhibitor reference for 
validating the docking results. The potential 
inhibitors were screened using DruLito based on 
Lipinski’s rule [20]. The molecular docking result 
was analysed by LigPlus V.2.0 to understand the 
details of the interactions between ligands and 
the protein. All visualizations of Biomolecules 
were conducted by PyMol Software.  
RESULTS  
 
The results of target selection showed that allicin 
interacted with leukocyte elastase (Supp. Data 
1). The 3D structure of leukocyte elastase was 
collected from the Protein Data Bank database 
(www.rcsb.org/) (ID number 2Z7F) and visualized 
using PyMOL software (Figure 1). Molecular 
docking modelling showed that allicin had the 
highest affinity with leukocyte elastase (-8,7 
kcal/mol) compared with epigallocatechin gallate 
(-7,2 kcal/mol), and pedunculagin (-7,8 kcal/mol). 
 
 
Figure 1: 3D structure of leukocyte elastase 
visualyzed using PyMOL software  
 
Moreover, molecular interaction showed that 
allicin was predicted to interact with leukocyte 
elastase via hydrogen bonds with of Gly 193, Ser 
195 and via hydrophobic interactions with Val 
190, Cys 191, Phe 192, Ser 214, Phe 215, and 
Val 216 (Figure 2). Epigallocatechin gallate was 
predicted to interact with leukocyte elastase via 
His 57, Asn 61, Tyr 94, Asp 102, Ser 195, Val 
216 via hydrogen bonds and with Ala 60, Pro 98, 
Leu 99B, Phe 192, Ser 214, and Phe 215 via 
hydrophobic interactions (Figure 3). 
Pedunculagin was predicted to interact with 
leukocyte elastase via Asn 61, Val 216 via 
hydrogen bond and with Phe 41, Cys 42, His 57, 
Cys 58, Ala 60, Val 62, Leu 99B, Phe 192, Ser 





Figure 2: Molecular docking between target protein 
(leukocyte elastase) and allicin: (a) allicin (red) binds 
leukocyte elastase   (green), (b) chemical structure of 
allicin, (c) interaction between allicin and target protein 
 





Figure 3: Molecular docking between target protein 
(leukocyte elastase) and epigalocathecin gallate. (a) 
epigalocathecin gallate (blue) bind to leukocyte 
elastase (green). (b) chemical structure of 
epigalocathecin gallate. (c) interaction between 





Figure 4: Molecular docking between target protein 
(leukocyte elastase) and pedunculagin. (a) 
pedunculagin (yellow) bind to leukocyte elastase 
(green). (b) chemical structure of pedunculagin. (c) 
interaction between pedunculagin and target protein 
 
Furthermore, using reverse docking it was 
discovered that allicin could bind to leukocyte 
elastase at the same binding site as the known 
inhibitors of leukocyte elastase, epigallocatechin 
gallate and pedunculagin (Figure 5). Then, using 
DruLito software, we found that allicin fulfills all 
the Lipinski's rule parameters. So, allicin is a 
potential anti-aging drug according to Lipinski's 




Leukocyte elastase is one of the proteins that 
has role in the aging mechanism, by degrading 
extracellular matrix components such as elastin. 
The inhibition of leukocyte elastase activity can  
 
 
Figure 5: Interaction between leukocyte elastase and 
inhibitors (allicin, epigalocathecin gallate, and 
pedunculagin) show that inhibitors bind with leukocyte 
elastase at the same site. Key: green (leukocyte 
elastase), red (allicin), blue (epigalocathecin gallate), 
and yellow (pedunculagin) 
 
Table 1: Lipinski's rule parameter to check 
compound’s drug-likeness 
 


















Allicin  162.02 0.237 0 1 
Epigalocathecin 
gallate  458.08 2.984 8 11 
Pedunculagin  759.89 -1.789 0 10 
 
interrupt the apoptosis cycle and oxidative stress 
[21]. Inhibition of leukocyte elastase has 
experimentally shown to be a treatment for 
premature aging [22]. Skin diseases such as 
neurodermatitis, acne, and keratosis could be 
reduced by leukocyte activity [23]. Premature 
aging processes induces loss of skin elasticity 
due to extracellular matrix. Selective and 
effective inhibition of leukocyte elastase can be a 
promising strategy for drug development for the 
treatment of aging [24]. 
 
Reverse docking is a powerful tool for drug 
repositioning and drug discovery. It involves 
docking a small-molecule drug/ligand in the 
potential binding cavities of a set of clinically 
relevant macromolecular targets [25,26]. Binding 
affinity is an important aspect that must be 
considered when studying interactions between 
molecules and macromolecules [27]. A lower 
binding affinity signifies that the compound 
requires very little energy to do the binding or 
interaction. The value of a lower binding affinity 
increases the potential for binding to the target 
protein [28,29]. Reverse docking results showed 
that allicin is a very good inhibitor for leukocyte 
elatase [23]. 
 
Residues that have the interaction with leukocyte 
elastase include Phe 192, ser 214, Phe 215, and 
Val 216, which is part of the primary structure of 
leukocyte elastase [30]. Residues Phe 192 and 
Val 216 are an active site on the leukocyte 
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elastase, so it can be said that allicin is capable 
of binding and inhibiting the activity of leukocyte 
elastase [31].  
 
Drug-like compounds must contain enough 
functionality to interact in a meaningful way with 
a protein [32], and the physicochemical 
properties of the compound will determine the 
quality of these interactions [33]. The 
physicochemical parameter ranges of Lipinski’s 
rule-of-five is molecular weight < 500, log P < 5, 





The findings of this study indicate that allicin has 
the capacity to serve as a leukocyte elastase 
inhibitor based on its binding affinity and 
intermolecular interactions. Thus, allicin is a 
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